Iliès Benotmane
YOU?
Author Swipe
View article: Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective Open
View article: P-1967. Characteristics of the first immunocompromised patients to receive Sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
P-1967. Characteristics of the first immunocompromised patients to receive Sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France Open
Background Immunocompromised patients account for a large proportion of COVID-19 hospitalizations and deaths, even in the most recent periods, despite having received several COVID-19 vaccine doses. Monoclonal antibodies effectively preven…
View article: Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France Open
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receiv…
View article: Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies
Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies Open
Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies
View article: #2639 Unraveling complement activation profiles on endothelial cells in healthy donors using an ex vivo model
#2639 Unraveling complement activation profiles on endothelial cells in healthy donors using an ex vivo model Open
Background and Aims Complement is involved in numerous kidney diseases. However, functional approaches to properly examine individual's susceptibility to complement dysregulation are limited. Method We assessed ex vivo complement activatio…
View article: Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients
Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients Open
The concomitant use of the monoclonal antibodies (mAbs) tixagevimab-cilgavimab has been originally authorized for pre-exposure prophylaxis of COVID-19.1 Although limited by a weak neutralizing activity,2 tixagevimab-cilgavimab has been the…
View article: Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding
Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding Open
View article: Prise en charge d’une infection virale chronique (BK polyomavirus) et d’une infection virale aigue (SARS-CoV-2) dans une population de transplantés rénaux
Prise en charge d’une infection virale chronique (BK polyomavirus) et d’une infection virale aigue (SARS-CoV-2) dans une population de transplantés rénaux Open
Kidney transplant recipients (KTR) are exposed to an increased risk of infection. These infections are a major cause of morbidity and mortality in this population of renal transplant recipients. BKPyV can lead to kidney graft loss. No spec…
View article: Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients
Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients Open
Repeated vaccination against SARS-CoV-2 increases serological response in kidney transplant recipients (KTR) with high interindividual variability. No decision support tool exists to predict SARS-CoV-2 vaccination response to third or four…
View article: Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients
Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients Open
Objective This single-center retrospective study evaluated the use of tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients (KTRs) during the omicron wave. Methods KTRs were deemed at high risk for moder…
View article: A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration
A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration Open
View article: Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study Open
Kidney transplant recipients (KTRs) displays marked inter-individual variations in magnitude of immune responses to anti-SARS-CoV-2 vaccination. The aim of this large single-center study was to identify the predictive factors for serologic…
View article: Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients
Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients Open
View article: Development and Validation of Multivariable Prediction Models of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Development and Validation of Multivariable Prediction Models of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients Open
Background Repeated vaccination against SARS-CoV-2 increases serological response in kidney transplant recipients (KTR) with high interindividual variability. No decision support tool exists to predict SARS-CoV-2 vaccination response in KT…
View article: Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant Open
View article: Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients
Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients Open
The combination of cilgavimab-tixagevimab (Evusheld™, Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is p…
View article: Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipients
Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipients Open
While the combination of casirivimab-imdevimab (Ronapreve™ Roche Regeneron) has been shown to confer satisfactory protection against the delta variant kidney transplant recipients (KTRs) with COVID-19, it has limited neutralizing activity …
View article: A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients Open
View article: Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia
Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia Open
View article: Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation Open
View article: Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients Open
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection, are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and defective response to vaccines. We observed that previous infe…
View article: Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series Open
International audience
View article: A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients Open
In immunocompetent subjects, the effectiveness of SARS-CoV-2 vaccines against the delta variant appears three- to five-fold lower than that observed against the alpha variant. Additionally, three doses of SARS-CoV-2 mRNA-based vaccines mig…
View article: Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients
Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients Open
The US FDA has recently authorized immunocompromised people to receive a third dose of mRNA Covid-19 vaccine following the two-doses regimen to further boost protection. Unfortunately, a non-negligible proportion of people treated with imm…
View article: L’immunosuppression et le défaut d’immunogénicité des vaccins à ARNm limitent la protection des patients transplantés vaccinés selon le schéma standard : plaidoyer pour une 3e dose
L’immunosuppression et le défaut d’immunogénicité des vaccins à ARNm limitent la protection des patients transplantés vaccinés selon le schéma standard : plaidoyer pour une 3e dose Open
INTRODUCTION: Les patients transplantés rénaux (TxR), à haut risque de développer une infection grave par le SARS-Cov2, bénéficient d’une priorité pour la vaccination. Cependant, comme les TxR reçoivent un traitement immunosuppresseur, ils…
View article: Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection
Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection Open
Transplant recipients, which receive therapeutic immunosuppression to prevent graft rejection, are characterized by high COVID-19-related mortality and defective response to vaccines. Having observed that previous infection by SARS-CoV-2 b…
View article: Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses Open
This study examines the antibody responses to a third dose (100 μg) of the mRNA-1273 SARS-CoV-2 vaccine among kidney transplant recipients in France who had not responded to 2 doses of the vaccine.
View article: Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19 Open
View article: Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy
Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy Open
View article: COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report
COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report Open